S. Debast

Clinical Microbiology and Infection · 2008–2014

A researcher in the Science corpus: 2 papers; trusts 0 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Whom S. Debast trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. E. Kuijper

Who trusts S. Debast overall

  1. J. H. Morse

Papers from S. Debast's perspective

Ordered by how strongly the researchers S. Debast trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. (The Lancet)
  2. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. (The Lancet)
  3. Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications (Annals of Surgery)
  4. AGREE II: advancing guideline development, reporting and evaluation in health care (Canadian Medical Association Journal)
  5. Treatment with monoclonal antibodies against Clostridium difficile toxins. (New England Journal of Medicine)
  6. Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec (Canadian Medical Association Journal)
  7. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. (Clinical Infectious Diseases)
  8. Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection (American Journal of Gastroenterology)
  9. Metronidazole is still the drug of choice for treatment of anaerobic infections. (Clinical Infectious Diseases)
  10. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease (American Journal of Gastroenterology)

Their papers